Author: Christos Chapeshis, Gerontologist, BScN, Dipl. W, Dipl. N, Dipl. CN, RN, CDTT, MScG
A deep tissue pressure injury begins under intact skin, where sustained pressure and shear damage muscle and subcutaneous tissue at the bone interface before any surface change is visible. By the time discolouration or a blood filled blister appears, the underlying damage is frequently already established, and standard offloading measures arrive too late to reverse it on their own. For device manufacturers, procurement teams and bedside clinicians in intensive care, gerontology and wound care, that gap between injury and visibility is the central problem this article addresses, drawing on the current international guideline on the subject (NPIAP, EPUAP and PPPIA, 2025).
What Distinguishes a Deep Tissue Pressure Injury From a Stage 1 Pressure Injury?
A deep tissue pressure injury originates at the muscle and bone interface, while a Stage 1 pressure injury begins as non-blanchable erythema confined to intact epidermis. The mechanisms differ as well as the depth. Deep tissue injury is driven by sustained deformation and shear at points of high mechanical load, compounded by ischaemia-reperfusion injury each time circulation is briefly restored and then compressed again. Stage 1 injury is closer to a surface inflammatory response to unrelieved pressure. The distinction matters clinically because a deep tissue pressure injury can progress to full-thickness tissue loss within days, even when a patient receives guideline-concordant repositioning and pressure redistribution throughout that period. A Stage 1 injury, by contrast, generally resolves once pressure is removed from the affected area. Clinicians who treat early discolouration as interchangeable with Stage 1 risk under-estimating how far the damage has already progressed beneath the surface.
Deep Tissue Pressure Injury vs Stage 1 Pressure Injury
| Feature | Deep Tissue Pressure Injury | Stage 1 Pressure Injury |
| Point of origin | Muscle and subcutaneous tissue at the bone interface | Epidermis and dermis |
| Surface appearance | Persistent purple or maroon discolouration, or a blood filled blister; skin may still be intact | Localised non-blanchable erythema over a bony prominence |
| Palpation | May feel firmer, boggier, or notably warmer or cooler than surrounding tissue | Tissue consistency is typically unchanged |
| Typical trajectory | Can evolve rapidly to full-thickness loss regardless of subsequent care | Usually reversible with pressure redistribution and offloading |
| Detection method | Often requires palpation, temperature and moisture assessment alongside vision | Primarily identified by visual inspection |
Palpation, temperature and moisture checks remain necessary alongside vision, particularly given how differently deep tissue injury can present across skin tones.
Why Is Deep Tissue Pressure Injury So Difficult to Detect Early?
Deep tissue pressure injury is difficult to detect early because its first changes occur beneath the skin, and visual assessment alone has been shown to under-recognise it in patients with darker skin tones. Nursing literature has documented how erythema-based assessment protocols, developed and validated predominantly on lighter skin, can miss the temperature, firmness and moisture changes that precede visible discolouration in patients with more pigmented skin (Osborne and Chambers, 2024). That gap has direct equity implications, since a patient whose earliest signs go unrecognised loses the window in which repositioning and offloading are still likely to prevent progression. Subepidermal moisture assessment technology has emerged as one response, measuring localised tissue oedema at the cellular level before any colour change is detectable by eye. The same literature frames it as a supplement to structured visual and tactile skin assessment, not something that replaces trained staff checking skin on a consistent schedule (Osborne and Chambers, 2024).
What Does the Trial Evidence Say About Prevention?
Repositioning and pressure redistribution remain the foundation of deep tissue pressure injury prevention, and current guidance sets minimum turning frequencies and support-surface criteria rather than treating any single interval as universally correct across all patients (NPIAP, EPUAP and PPPIA, 2025). A randomised controlled trial comparing a dedicated turning and positioning system against usual-care turning and positioning devices in intensive care patients reported favourable clinical and cost outcomes for the structured system in preventing hospital acquired pressure injury (Kapp et al., 2023). That trial evidence backs automated, consistent repositioning as a genuine complement to manual nursing care, especially on units where staffing ratios make strictly manual two-hourly turning hard to sustain across every shift; it does not remove the need for clinical judgement at the bedside.
ABeWER‘s own implementation of this principle, multiTURN® 6, applies automated 30° lateral turning at intervals of 30, 60 or 90 minutes per side, an alternating pressure cycle of 12, 18 or 24 minutes, and Continuous Low Pressure distributed across the support surface. An anti-collapse system, head elevation of around 45° combined with foot elevation, and a weight capacity of 180 kg extend its intended use across most adult acute and long-term care populations. The mattress measures 200×90×23 cm, carries CE marking under Regulation (EU) 2017/745, and is manufactured to EN ISO 13485:2016, with quiet operation, a static mode, an automatic panel lock after three minutes, and CPR rapid deflation for emergency use.
Clinical uncertainty: No published trial has evaluated multiTURN® 6 specifically against deep tissue pressure injury incidence, and no current tool reliably predicts which patients with early tissue changes will progress to full-thickness loss. Subepidermal moisture assessment and automated turning systems help, but neither one replaces regular hands-on skin checks and clinical judgement at the bedside.
Implications for Bedside Practice and Procurement
For clinicians, the practical takeaway is to combine frequent, skin-tone-aware assessment with guideline-concordant repositioning and support surfaces built for consistent, automated turning, rather than treating any one measure as sufficient on its own. For procurement and hospital technology teams, the same trial evidence that supports automated turning and positioning systems in the ICU is a reasonable basis for evaluating similar systems in step-down and long-term care settings, where the staffing constraint behind manual repositioning is often more severe rather than less. A fuller review of deep tissue pressure injury mechanisms, staging and prevention evidence, compiled by ABeWER’s clinical team, is available at abewer.com.
References
NPIAP, EPUAP and PPPIA (2025) Prevention and Treatment of Pressure Ulcers/Injuries: Clinical Practice Guideline, 4th edn.
Kapp, S. et al. (2023) ‘Clinical and cost effectiveness of a system for turning and positioning intensive care unit patients, when compared to usual care turning and positioning devices, for the prevention of hospital-acquired pressure injuries: a randomised controlled trial’, International Wound Journal.
Osborne, S. and Chambers, D. (2024) ‘Shedding new light for nurses: enhancing pressure injury prevention across skin tones with sub-epidermal moisture assessment technology’, Journal of Advanced Nursing.
